NCT01596712View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Allergy
Interventions
DRUG

QGE031

QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.

DRUG

Placebo

Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.

Trial Locations (1)

228-8520

Novartis Investigative Site, Sagamihara

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY